QUIA PHARMA AB (OSTO:QUIA) EBIT : kr-28.66 Mil (TTM As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is QUIA PHARMA AB EBIT?

QUIA PHARMA AB's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was kr-21.60 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-28.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. QUIA PHARMA AB's annualized ROC % for the quarter that ended in Dec. 2024 was -128.00%. QUIA PHARMA AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -25,864.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. QUIA PHARMA AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -95.75%.

QUIA PHARMA AB EBIT Historical Data

The historical data trend for QUIA PHARMA AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QUIA PHARMA AB EBIT Chart

QUIA PHARMA AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-24.93

-17.57

-15.79

-15.51

-28.66

QUIA PHARMA AB Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT	Get a 7-Day Free Trial															-6.95	-9.01	-6.50	-7.07	-21.60

Competitive Comparison of QUIA PHARMA AB's EBIT

For the Biotechnology subindustry, QUIA PHARMA AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QUIA PHARMA AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where QUIA PHARMA AB's EV-to-EBIT falls into.

Save

QUIA PHARMA AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-28.66 Mil.

QUIA PHARMA AB (OSTO:QUIA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

QUIA PHARMA AB's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-43.196 * ( 1 - 0% )	/	( (43.172	+	24.324)	/ 2 )
=	-43.196	/	33.748
=	-128.00 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	42.566	-	2.968	-	( 2.578	-	max(0, 7.89	-	4.316	+	2.578	))
=	43.172

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	22.749	-	3.774	-	( 0.002	-	max(0, 6.395	-	1.046	+	0.002	))
=	24.324

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

QUIA PHARMA AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-43.194	/	( ( (0.272 + max(-7.89, 0))	+	(0.062 + max(-6.395, 0)) )	/	2 )
=	-43.194	/	( ( 0.272	+	0.062 )	/	2 )
=	-43.194	/	0.167
=	-25,864.67 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(2.968	+	0	+	4.922)
=	-7.89

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(3.774	+	0	+	2.621)
=	-6.395

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

QUIA PHARMA AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	-28.664	/	29.936
	=	-95.75 %

QUIA PHARMA AB EBIT Related Terms

Thank you for viewing the detailed overview of QUIA PHARMA AB's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

QUIA PHARMA AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QUIA PHARMA AB (OSTO:QUIA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

99B0:Germany

Address

Virdings Alle 32 B, Uppsala, SWE, 754 50

Website

https://www.quiapeg.com

QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.

QUIA PHARMA AB Headlines

No Headlines